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Summary: 
The diagnosis of dyslipidemia is increasing both in adulthood and in childhood due not only to the steadily increasing prevalence of obesity but also to a rise of medical attention in detecting unfavorable genetic conditions in patients of all ages. Attempts in life-style changes are frequently failing and, thus, the pharmacological treatment of dyslipidemia is wide spreading in medical practice in order to reduce cardiovascular risk. In childhood, statins are authorized by 8 years of age. Nevertheless, data on their long-term safety and efficacy are still lacking, especially in ones with high cardiovascular risk and/or primary dyslipidemia such as homozygous familial hypercholesterolemia, considerable as a mainly exclusively pediatric disease. Thus, new pharmacological approaches are needed and have to be evaluated in all the categories of patients. In this context, the update and the critical revision of blooming new medications has became a new duty for scientists and clinicians.  
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Hypercholesterolemia is a well-known risk factor to develop cardiovascular disease both in childhood and adulthood. The cornerstone of lipid-lowering treatment is a healthy lifestyle but diet alone fails to lower cholesterol levels to acceptable values namely in patients with genetic hypercholesterolemia needing pharmacological treatment [1].
Despite results already obtained in lowering cholesterol, over recent years, many attempts of new drugs to limit the progression of atherosclerosis are bloomed. 
The urgent necessity to find new drugs arises by common dilemmas that lipidologists may face in clinical practice: specifically, patients on traditional lipid-lowering medications may manifest intolerance and/or do not reach therapeutic goals despite maximum doses of conventional drugs, mainly those with severe forms of hypercholesterolemia.

What’s new about statins?
Statins efficacy is already well established both in adult and in children and they are currently the mainstay in the treatment of hypercholesterolemia. 
A recent study confirms the hypothesis that statins not only decrease LDL-cholesterol (LDL-C) levels, but also may have lipid-independent pleiotropic effects altering inflammatory responses and local atherosclerotic plaque morphology mediated through the inhibition of mevalonate pathway and the direct effects on atherosclerotic plaque macrophages [2]. 
Considering the safety concerns posed for long-term treatment with statins, especially for those beginning in children and adolescents, many efforts have been made to overcome these problems. 
New pharmacological formulations are exploring statin-containing nanoparticles with a higher bioavailability and a reduction of their potential toxicity and adverse effects [3]. In this technology (involving liposomes, polymeric particles, hydrogels, micelles, inorganic/solid particles, dendrimers, nanotubes and quantum dots), therapeutic agents are typically encapsulated, entrapped, adsorbed or chemically attached to the nanoparticle surface in order to prolong their presence into circulation and microcirculation, to specifically accumulate them in target tissues, to select cellular uptake by target endothelial cells and to control their release [4]. Recently, in an apolipoprotein E-knockout mouse model of atherosclerosis, the in vivo use of intravenously prolonged low dose as well as short-term high dose statin-reconstituted high-density lipoproteins (rHDL) nanoparticles shows that they accumulate in atherosclerotic lesions in which seem to directly suppress plaque macrophages without exhibiting myo- or hepatotoxic effects [2].
Another way to improve the statin therapy could derive from data evaluating genetic aspects. Recent studies have been performed on the polymorphism of P450 oxidoreductase (POR) enzyme involved in transferring electrons from nicotinamide adenine dinucleotide phosphate (NADPH) to cytochrome P450 (CYP) enzymes including CYP3A, which metabolize atorvastatin and simvastatin. Children with familial hypercholesterolemia (FH) carriers of POR*28 allele seem to be associated with reduced effect of atorvastatin on total cholesterol (TC) and LDL-C, so this allele identifies subjects that may require higher atorvastatin doses to achieve full therapeutic benefits [5]. Nevertheless, published data are discordant and considering the current state-of-the-art further studies involving wider and different populations are required [6]. 
Combined therapy
A way to improve the safety of lipid-lowering treatment is to associate different now agents at lower doses. 
Ezetimibe decreases cholesterol absorption through inhibition of Niemann-Pick C1-like 1 protein leading to a clinical reduction of LDL-C by 23%. It seems to be well tolerated and is nowadays commonly used in association with statins. Available data suggest that this combination may not restore endothelial dysfunction [7] and that ezetimibe does not influence high-density-lipoprotein cholesterol (HDL-C), a well-known independent risk factor for cardiovascular diseases.
However, very recent data from the IMPROVED-IT study, enlisting about 18.000 adults affected by acute coronary syndrome, have been disclosed: relative to simvastatin alone, the association of simvastatin and ezetimibe reduced ischemic stroke by 21% and myocardial infarction by 13% and led to a significantly lower incidence of the primary combined endpoint (cardiovascular death, myocardial infarction, re-hospitalization for unstable angina, coronary revascularization or stroke; 34.7% vs. 32.7%, P=0.016) [8].
Even if these recent findings may help in answering some questions about ezetimibe studies in children and adolescent are still needed.
In terms of combined-therapies, old lipid lowering agents like resins deserve to be mentioned because of their recent discovered positive impact on glucose homeostasis [9]. 
Inhibition of PCSK9 pathway
Subjects with loss-of-function mutations in the pro-protein convertase subtilisin/kexin-9 (PCSK9) gene have less lysosomal degradation of the LDL-C receptor (LDLR), greater surface expression of the LDLR, reduced plasma LDL-C and reduced vascular risk during their lifetimes [10]. The inhibition of PCSK9 pathway immediately appears one of the most promising novel targets for additional LDL-C reduction [11]. Alirocumab (REGN-727), evolocumab (AMG-145), and bococizumab (RN-316) are human monoclonal antibodies that bind circulating PCSK9 and block its interactions with surface LDLR. They have recently demonstrated a great potentiality in reducing LDL-C in adulthood and alirocumab is now tested in phase I-III clinical trials [12]. Data from the ODYSSEY ALTERNATIVE study, reported at the last American Heart Association meeting, demonstrate that alirocumab provides significantly higher lipid reduction in statin-intolerant patients with high LDL-C levels relative to ezetimibe. Specifically, 314 patients enrolled in the study were randomized to receive alirocumab as a 75-mg self-administered injection fortnightly (n=126), 10 mg ezetimibe daily (n=125) or 20 mg atorvastatin daily (n=63) for 24 weeks. At the end of the study, subjects receiving alirocumab had a reduction in LDL-C concentrations of 45% from baseline despite the 14.6% reduction obtained in patients receiving ezetimibe [8]. Nevertheless, all these agents need to be given as subcutaneous injections every 2 weeks or monthly because of their relatively short in vivo half-lives: this aspect could increase the cost/benefit ratio limiting their use exclusively in high-risk patients and making their diffusion in childhood problematic. Moreover, evidences on their efficacy to improve cardiovascular outcome should be obtained only in 2016–18. Recently, PCSK9-specific active vaccines approaches have being developed and their long-term efficacy and safety have being assessed in different preclinical models in order to circumvent the drawbacks of alirocumab [13]. 
Therapies targeting HDL
To improve cardiovascular health, other suitable drugs targets have been identified. Clinical trials on therapies targeting HDL-C particle metabolism as cholesterol ester transfer protein (CETP) inhibitors or apoA1 mimetics are in progress. Recalling physiology, CETP shuttles cholesterol esters from HDL-C to the atherogenic LDL-C and very-low-density lipoprotein (VLDL) in exchange for triglycerides, resulting in a decrease in HDL-C, with a concomitant increase in LDL-C. To date, 4 small molecules inhibitors of CETP reach the clinical stage of development. Torcetrapib hopes use felt down in December 2006 when it was demonstrated to be associated with increased cardiovascular mortality in the large phase 3 end point trial Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE). This adverse effect was correlated to its off-target actions in increasing aldosterone, corticosterone, endothelin-1 levels and, thus, blood pressure [14]. Despite an increase in HDL-C levels, an analogue unhappy end marked the second irreversible CETP inhibitor, dalcetrapib [15]. Actually, other 2 drugs, anacetrapib and evacetrapib, are going to be developed. Both raise HDL-C by 80–120% and reduce LDL-C by 30–40%. Outcome studies are underway and results are expected in 2016–17 [16]. 
Therapy for HoFH
The dramatic cardiovascular outcomes of some rare conditions such as homozygous FH (HoFH) [17] and homozygous lipoprotein lipase deficiency (LPLD; familial chylomicronaemia) have allowed the development and the use of some orphan drugs. Being rare diseases, examples and resources are scarce. Mipomersen, an antisense oligonucleotide, targets the apolipoprotein B [an essential component of all atherogenic lipoproteins and Lp(a)] mRNA mainly in the liver causing its cleavage and reduces LDL-C by 25% in HoFH patients [18, 19]. Lomitapide, a microsomal transfer protein (MTP) inhibitor, targets the lipidation of apolipoprotein B and can reduce LDL-C by 50% in HoFH patients [20]. The conceptual basis for inhibition of MTP with lomitapide partly derives from the observation in human beings of a rare recessive genetic disorder known as abetalipoproteinaemia, in which functional MTP is absent, VLDL cannot be secreted from hepatocytes, and there are no apolipoprotein B-containing lipoproteins in the systemic circulation [20]. Some severe side-effects are described for both drugs and comprise injection site reactions, transient influenza-like symptoms, diarrhea, nausea, abdominal pain, hepatic fat accumulation leading to steatosis and transaminase elevations for the latter. Data from other patients’ populations (heterozygous FH subjects on high-dose conventional therapies or primary hypercholesterolemia ones intolerant to conventional drugs) are going to be develop and first data appear variable [21]. Nowadays, mipomersen has only an orphan drug licence in USA and lomitapide is licensed for HoFH both in Europe and USA. 
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